Search Within

Gregory J Riely

Formats
  1. Journal Article (295)
  2. Meeting Abstract (265)
  3. Book Section (16)
  4. Guidelines (15)
  5. Conference Paper (4)
  6. Review (4)
  7. Editorial (3)
  8. Book Whole (1)
  9. Correspondence (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (605)
  2. Solid Tumor Oncology Division (605)
  3. Thoracic Oncology (605)
  4. Department of Pathology and Laboratory Medicine (262)
  5. GSK Faculty (248)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Mark Kris (222)
  2. Marc Ladanyi (188)
  3. Helena Yu (108)
  4. Maria Arcila (85)
  5. Vincent Miller (79)
  6. Charles Rudin (76)

More People

Years
  1. 2025 (9)
  2. 2024 (25)
  3. 2023 (45)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (29)

More Years

Publications
  1. Journal of Clinical Oncology (157)
  2. Journal of Thoracic Oncology (113)
  3. Clinical Cancer Research (46)
  4. Annals of Oncology (32)
  5. Journal of the National Comprehensive Cancer Network (26)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (175)
  2. Elsevier Inc. (137)
  3. American Association for Cancer Research (77)
  4. Oxford University Press (39)
  5. Harborside Press (26)
  6. Elsevier Science, Inc. (23)

More Publishers

Results (605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Drilon, A. E. D.; Varghese, A. M.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comparison of the KRAS/EGFR mutation profile and survival of "collegiate smokers" and never smokers with advanced lung cancers
    Meeting Abstract

    Varghese, A. M.; Sima, C. S.; Chaft, J. E.; Johnson, M. L.; Janjigian, Y. Y.; Drilon, A. E. D.; Yu, H. A.; Riely, G. J.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ)
    Meeting Abstract

    Scagliotti, G.; Kim, D. W.; Shaw, A. T.; Ou, S. H. I.; Riely, G. J.; Gettinger, S. N.; Besse, B.; Thomas, M.; Salgia, R.; Wilner, K. D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations
    Meeting Abstract

    Riely, G. J.; Brahmer, J. R.; Planchard, D.; Crino, L.; Doebele, R. C.; Lopez, L. A. M.; Gettinger, S. N.; Schumann, C.; Li, X.; Atkins, B. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of cixutumumab (IMC-A12) in thymic malignancies
    Meeting Abstract

    Rajan, A.; Riely, G. J.; Carter, C. A.; Thomas, A.; Khozin, S.; Bergagnini, I.; Berman, A. W.; Scepura, B.; Szabo, E.; Lee, M. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Clinical characteristics of ALK plus NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management
    Meeting Abstract

    Otterson, G. A.; Riely, G. J.; Shaw, A. T.; Crino, L.; Kim, D. W.; Martins, R.; Salgia, R.; Zhou, C.; Solomon, B. J.; Wilner, K. D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Characteristics of NSCLCs harboring NRAS mutations
    Meeting Abstract

    Ohashi, K.; Sequist, L. V.; Sos, M.; Chen, X.; Rudin, C. M.; Moran, T.; Arcila, M. E.; Lovly, C. M.; Vnencak-Jones, C. L.; Sasaki, H.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kim, D. W.; Ahn, M. J.; Shi, Y.; De Pas, T. M.; Yang, P. C.; Riely, G. J.; Crino, L.; Evans, T. L.; Liu, X.; Han, J. Y.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)
    Meeting Abstract

    Johnson, M. L.; Yu, H. A.; Hart, E. M.; Worden, R.; Rademaker, A.; Gupta, R.; Miller, C.; Patel, J. D.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • 5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial
    Meeting Abstract

    Drilon, A. E. D. C.; Kyuichi, K.; Huberman, K. H.; Sima, C. S.; Fiore, J. J.; Yu, H. A.; Varghese, A. M.; Sumner, D. K.; Travis, W. D.; Heguy, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save